Navigation LinksTop Biology NewsTop Medical NewsTop Biology TechnologyTop Medical Technology


Mathematics and Biochemistry Research Earn Top Prize at Nation's Premier High School Science Competition

11/7/2009

0

GOOD
CAMBRIDGE, Mass., Nov. 7, Research projects in the areas of mathematics and biochemistry scored top marks this evening, as Tim Kunisky of Livingston, NJ and the team of Benjamin Song and Quan (Jack) Chen of Audubon, PA received the highest honors at the Region Five Finals of the 2009 Siemens Competition in Math, Science & Technology, the nation's premier high school sci... [Comments]

Microbix Biosystems Re-files Annual Results With OSC

11/6/2009

1

GOOD
TORONTO, Nov. 6 /PRNewswire-FirstCall/ - Microbix Biosystems Inc. (the "Company") announces today that it has re-filed the Form 52-109F1 Certification of Annual Filings of William Gastle, the Chief Executive Officer and James Long, the Chief Financial Officer (the "Officer's Certificates") dated January 12, 2009 in connection with the annual audited financial statements for the year ended... [Comments]

Reissue with Tables: BioSpecifics Technologies Corp. Reports Third Quarter 2009 Financial Results

11/6/2009

0

GOOD
LYNBROOK, N.Y., Nov. 6 BioSpecifics Technologies Corp. (Nasdaq: BSTC ), a biopharmaceutical company developing first-in-class collagenase-based products, today announced its financial results for the third quarter ended September 30, 2009. "We were extremely happy that, in September of this year, the FDA's Arthritis Advisory Committee unanimously recommend... [Comments]

Helix BioPharma to Present at Merriman Curhan Ford's Investor Summit 2009 on November 10th

11/6/2009

0

GOOD
AURORA, Ontario, Nov. 6 Helix BioPharma Corp. (TSX, FSE: "HBP" / Pink Sheets: HXBPF) today announced that John Docherty, president and chief operating officer, will present at Merriman Curhan Ford's 6th annual Investor Summit on November 10, 2009 at 4:00 PM at the Sofitel Hotel in New York City. Mr. Docherty will provide an overview of the Company's leading produ... [Comments]

Myriant Technologies LLC, Uhde Corporation of America and Uhde GmbH Announce Alliance for Engineering, Procurement & Construction of World Scale Renewable Succinic Acid Plants

11/6/2009

0

GOOD
QUINCY, Mass., Nov. 6 Myriant Technologies LLC ("Myriant"), a privately-held, biotech developer and manufacturer of renewable bio-chemicals, Uhde Corporation of America and its preferred technology provider Uhde GmbH, one of the world's leading engineering contractors (jointly "Uhde"), announced an alliance for the engineering, procurement & construction (EPC) of Myria... [Comments]

EUCODIS Bioscience to Explore Novel Enzymatic Activities in Antarctic Bacteria Library From Bio Sidus

11/6/2009

0

GOOD
VIENNA, Austria, November 6 EUCODIS Bioscience, a companydeveloping, customizing, manufacturing, and marketing enzymes for thechemical industry announced today that it has entered into a researchagreement with Bio Sidus, the leading biopharmaceutical company in LatinAmerica. The agreement gives EUCODIS Bioscience exclusive access - for the searchof enzym... [Comments]

NeurogesX Reports Third Quarter 2009 Results

11/6/2009

0

GOOD
SAN MATEO, Calif., Nov. 6 3Q09 Corporate Highlights: Completed transfer of Qutenza(TM) E.U. Marketing Authorization to Astellas Pharma Europe Ltd. Made significant progress in commercial readiness activities Expanded management team to include VP Sales; Senior Director, Marketing; and Director, Commercial Operations Appointed Bradford S. Good... [Comments]

Calbiotech Awarded U.S. Army Phase I SBIR Research Contract to Develop Analyte Specific Reagents for the Diagnosis of Dengue Fever Virus

11/6/2009

0

GOOD
SPRING VALLEY, Calif., Nov. 6 Calbiotech, Inc. announced today that it has been awarded a Small Business Innovative Research (SBIR) Phase I contract by the U.S. Army Medical Research and Material command. Under terms of the agreement, Calbiotech will develop analyte specific reagents (ASRs) for the diagnosis of Dengue virus. Dengue virus is a mosquito-born flavivir... [Comments]

Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting

11/6/2009

0

GOOD
CALGARY, Nov. 6 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced updated results from a Phase II study of intravenous REOLYSIN(R) in patients with sarcomas metastatic to the lung in a poster presentation at the 15th Annual Connective Tissue Oncology Society Meeting held in Miami Beach, Florida, from November 5th to 7th.... [Comments]

Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting

11/6/2009

0

GOOD
HAYWARD, Calif., Nov. 6 Intarcia Therapeutics, Inc. delivered two presentations today on its ITCA 650 (DUROS® continuous delivery of exenatide) program for the treatment of type 2 diabetes at the Ninth Annual Diabetes Technology Meeting in San Francisco, CA: (Logo: http://www.newscom.com/cgi-bin/prnh/20050301/SFTU126LOGO ) Continuous Subcutaneous Deliver... [Comments]

[next]
(Date:11/4/2009)...mber 4, 2009 Childhood obesity in the United Stat...n one fourth of advertising on daytime and prime t...continuing questions about the role television pla...sue of the Journal of Nutrition Education and Beh...dren might be a large contributor to the problem. ...
(Date:11/4/2009)...atory that deciphered the DNA codes, or genomes, o...k, has joined The Genome 10K Project, an internati...NA sequences on 10,000 species of animals for cond...ly can not be achieved. , Participating in The G...in the Nov. 5, 2009 issue of the Journal of Hered...
(Date:11/4/2009)... Calif., Oct. 19 Spectros, develop...and imaging devices which shed light on life-threa...d exclusive distribution deals for both its T-Stat...ts covered include Australia, New Zealand, The Ne..., Italy, France, Spain, Portugal, Poland, Greece, ...
Breaking Biology News(10 mins):TV bombards children with commercials for high-fat and high-sugar foods 2TV bombards children with commercials for high-fat and high-sugar foods 3Singapore scientists join international study of 10,000 vertebrates' genomes 2Spectros Signs New International Distribution Deals 2Rib X Pharmaceuticals Inc Co Founder Thomas A Steitz Ph D Awarded the 2009 Nobel Prize in Chemistry 5296 1Rib X Pharmaceuticals Inc Co Founder Thomas A Steitz Ph D Awarded the 2009 Nobel Prize in Chemistry 5296 2Rib X Pharmaceuticals Inc Co Founder Thomas A Steitz Ph D Awarded the 2009 Nobel Prize in Chemistry 5296 3Rib X Pharmaceuticals Inc Co Founder Thomas A Steitz Ph D Awarded the 2009 Nobel Prize in Chemistry 5296 4Injury and hazards in home health care nursing are a growing concern 59078 1Injury and hazards in home health care nursing are a growing concern 59078 2Injury and hazards in home health care nursing are a growing concern 59078 3NIH grant will boost electron microscopy at Brandeis 10290 1NIH grant will boost electron microscopy at Brandeis 10290 2
...LLA, CA Ever since insects developed a taste for ...e limited resources to out-compete their neighbors... against hungry insects. Now, an international tea...al Studies and the Institute of Investigaciones Fi...EVA) has discovered how plants weigh the tradeoffs...
...NGHAM, Ala. The human immunodeficiency virus (HIV... any successful AIDS vaccine must keep pace with t...s, according to researchers at the University of A...xford in England. , A new study better describes ... different "escape mutations" that help keep the v...
...tists from Queen Mary, University of London have d...y be the key to beating a viral infection which is...ommunities of common frogs (Rana temporaria) are b...ated to be killing tens of thousands of frogs in t... surrounding lawn becomes strewn with dead frogs, ...
Other Biology News:Understanding natural crop defenses 2Understanding natural crop defenses 3HIV adapts to 'escape' immune response 2Frog's immune system is key in fight against killer virus 2
IMAGEQUANT 400 IQTL from GE Healthcare, formerly Amersham Biosciences
APO-BrdU TUNEL Assay Kit with Alexa Fluor 488 anti-BrdU from Molecular Probes (Invitrogen)
Flammable Chemical Cabinets, Justrite Model RL25762Y from South Coast Enterprises
IMAGEQUANT 300 IQTL from GE Healthcare, formerly Amersham Biosciences
Biology Products:
(Date:11/5/2009)...wire-FirstCall/ -- ThermoGenesis Corp. (Nasdaq: K...or processing and storing adult stem cells, today ...010. ,, For the quarter ended September 30, 200...a 15 percent increase over revenues of $4.5 millio...d the key contributors to the growth in revenues i...
(Date:11/5/2009)...FirstCall/ -- Cepheid (Nasdaq: CPHD ) today annou...ollowing investor conferences, and invited investo... Credit Suisse Healthcare Conference, Phoenix, AZ,... a.m. Mountain Time, NASDAQ OMX 2... Tuesday, 1 December, 2009 at 10.45 a.m. Green...
(Date:11/5/2009)...SpineSmith Partners has signed an initial agreemen...old that mimics the structure of natural cancellou...l products by SpineSmith,s Research and Developmen...affold represents a significant advancement in tec...t for the delivery of adult stem cells for skeleta...
(Date:11/5/2009)...ngs a new look to Pro Repro , ...sional Reprographics, Orange County’s fastes...ent Brooke Sanders to the company. Brooke joins th...ition of Brooke to the company represents continue...raphics., , ,Brooke brings with her over five year...
Breaking Biology Technology:ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 2ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 3ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 4ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 5ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 6ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 7ThermoGenesis Reports 15 Percent Increase in First Quarter Revenues; Improved Bottom Line 8Cepheid to Webcast Upcoming Financial Presentations 2SpineSmith Partners and GenOsteo Announce Collaborative Product Development Agreement 2
... Inc. today announced that it has been awarded a $...earch (SBIR) grant from the National Institute of ...ional Institutes of Health (NIH). The grant will ...gy and pharmacology studies of the company,s propr...s being developed as a potential treatment for gro...
...e sublingual lozenge) as the first sleep aid speci...e-night awakenings , , PT. RICHMOND, Calif., ...ely-held specialty pharmaceutical company, announc...e U.S. Food and Drug Administration (FDA) that the...olpidem tartrate sublingual lozenge) has been acce...
...Technologies, Inc. (Nasdaq: NTII ) (NTI(R)) toda...P. (Celtic) has provided an update on XERECEPT(R)....related to XERECEPT to Celtic in,November 2005. NT...he,achievement of certain regulatory approvals, an... is also entitled to receive profit-sharing paymen...
Other Biology Technology:Bolder BioTechnology Receives $1.9 Million NIH Grant to Continue Development of Long-Acting Growth Hormone Product 2Transcept Pharmaceuticals Announces FDA Acceptance for Review of New Drug Application for Intermezzo(R) 2Transcept Pharmaceuticals Announces FDA Acceptance for Review of New Drug Application for Intermezzo(R) 3Transcept Pharmaceuticals Announces FDA Acceptance for Review of New Drug Application for Intermezzo(R) 4Transcept Pharmaceuticals Announces FDA Acceptance for Review of New Drug Application for Intermezzo(R) 5Neurobiological Technologies' Partner, Celtic Pharma, Provides Update on XERECEPT(R) Clinical Program and Planned Sale in 2009 2Neurobiological Technologies' Partner, Celtic Pharma, Provides Update on XERECEPT(R) Clinical Program and Planned Sale in 2009 3Neurobiological Technologies' Partner, Celtic Pharma, Provides Update on XERECEPT(R) Clinical Program and Planned Sale in 2009 4